By combining epigenetics with AI, our tests go beyond traditional tests to measure an individual's unique molecular biology.
Our blood tests do not require fasting or exposure to radiation that could increase cancer risk.
Our technology combines epigenetics, genetics, and AI to more comprehensively assess heart health even in the absence of risk factors.
Our tests are clinically validated, backed by peer-reviewed publications and have high sensitivity and specificity.
Samples can be collected via phlebotomy in a clinical setting or patients can request a test virtually and collect their sample at home.
Investors
2026 Cardio Diagnostics, Inc.
